Investor Login

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

BOSTON, June 01, 2026 -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027.

Aura - 06/02/2026

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

BOSTON, May 21, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data from two separate assessments of AKY-2519 – a clinical imaging and dosimetry assessment in patients with mCRPC and a clinical imaging assessment in patients with various solid tumor types – demonstrated robust tumor uptake and limited normal tissue exposure. These findings, which supported the advancement of a broad clinical development program for AKY-2519, will be presented in two poster presentations at the upcoming 2026 ASCO Annual Meeting, being held May 29 – June 2, 2026, in Chicago.

0-Homepage Feature / 0-Megaphone / Aktis Oncology - 05/21/2026

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

BOSTON, May 04, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the initiation of a Phase 1b clinical trial of AKY-25191 in patients with metastatic castration-resistant prostate cancer (mCRPC). The mCRPC-dedicated Phase 1b trial is part of Aktis’ clinical development strategy to develop AKY-2519 broadly in B7-H3 expressing tumors. Aktis plans to initiate a Phase 1b basket trial in lung, colorectal, and other high B7-H3 expressing solid tumors in the second half of 2026.

Aktis Oncology - 05/04/2026

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519

BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate and lung cancers, and is the second clinical stage miniprotein radioconjugate discovered using Aktis’ proprietary platform. The Company’s lead miniprotein radioconjugate, AKY-1189, targeting Nectin-4, is currently enrolling patients in a Phase 1b clinical study. Aktis’ miniprotein radioconjugates are designed to selectively deliver actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to target-expressing tumors.

Uncategorized - 04/15/2026

Horizon Quantum and IonQ Enter into Strategic Agreement to Unlock Quantum Potential

SINGAPORE, COLLEGE PARK, Md., April 9, 2026 — Horizon Quantum Holdings Ltd. (“Horizon Quantum”), a pioneer of software infrastructure for quantum applications and IonQ — the world’s leading quantum platform company — today announced a strategic agreement. Horizon Quantum will purchase one of IonQ’s first 6th-generation, chip-based 256-qubit trapped-ion systems, in furtherance of Horizon Quantum’s mission to unlock the full potential of quantum computing with its software platform. The acquisition of the 256-qubit system marks a further step in Horizon Quantum’s efforts to enable broad quantum advantage.

Horizon - 04/09/2026

Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG

SAN CARLOS, Calif.--April 2, 2026--Glycomine, Inc. announced today that enrollment has been completed in the Phase 2b POLAR study, a global, randomized, double-blind, placebo-controlled clinical trial evaluating GLM101 for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). PMM2-CDG is a rare genetic disorder that causes serious neurological and multisystem impairments. More than 90% of patients with PMM2-CDG have ataxia, a key neurological manifestation and driver of disease burden. There are currently no approved treatments for PMM2-CDG.

Glycomine - 04/02/2026

Horizon Quantum, a Leading Quantum Software Infrastructure Company, Closes its Business Combination with dMY Squared

SINGAPORE AND LAS VEGAS, NV, March 19, 2026 — Horizon Quantum Computing Pte. Ltd. (“Horizon Quantum”), a pioneer of software infrastructure for quantum applications, today announced that it has completed its previously announced business combination (the “Business Combination”) with dMY Squared Technology Group, Inc. (“dMY”) (OTC: “DMYY”, “DMYYU” and “DMYYW”), a publicly traded special purpose acquisition company. The Business Combination was approved by dMY’s shareholders at dMY’s special meeting held on March 17, 2026. On March 20, 2026, the combined company’s Class A ordinary shares and warrants will begin trading on Nasdaq under the ticker symbols “HQ” and “HQWWW,” respectively.

Horizon - 03/19/2026

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

BOSTON, Feb. 24, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AKY-1189 for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have progressed on or after prior systemic therapies. Generated using Aktis’ miniprotein radioconjugate platform, AKY-1189 is designed to deliver actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to Nectin-4 expressing tumors. Approximately 80 – 90% of urothelial cancer patients show positive expression of Nectin-4.

Aktis Oncology - 02/24/2026

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the pricing of its upsized initial public offering of 17,650,000 shares of its common stock at a price to the public of $18.00 per share. In addition, Aktis has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Aktis, are expected to be approximately $318.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock are being offered by Aktis. Aktis’ common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “AKTS” on January 9, 2026. The offering is expected to close on January 12, 2026, subject to satisfaction of customary closing conditions.

Aktis Oncology - 01/09/2026
logo_white
veteran_logo_white
NVCA
bio
nc-biotech